NCT05317858 2026-04-16
LIMITLESS
InSightec
Phase 3 Recruiting
Clinical Trials
18 trialsNCT03175432 2026-04-15
Bevacizumab and Atezolizumab With or Without Cobimetinib in Treating Patients With Untreated Melanoma Brain Metastases
M.D. Anderson Cancer Center
Phase 2 Active not recruiting
NCT04729959 2026-04-01
Testing the Addition of the Immune Therapy Drugs, Tocilizumab and Atezolizumab, to Radiation Therapy for Recurrent Glioblastoma
National Cancer Institute (NCI)
Phase 2 Active not recruiting
NCT05746481 2026-01-22
Tiragolumab and Atezolizumab in Patients With Non-squamous Non-small Cell Lung Cancer (NSCLC) and Untreated Brain Metastases
University of Pittsburgh
Phase 2 Terminated
NCT05423210 2025-12-22
Atezolizumab and Pre-Surgical Brain Radiation Therapy for Glioblastoma Multiforme
Stony Brook University
Phase EARLY_PHASE1 Recruiting
NCT05039281 2025-12-19
Atezolizumab and Cabozantinib for the Treatment of Recurrent Glioblastoma
M.D. Anderson Cancer Center
Phase 1/2 Recruiting
NCT06069726 2025-10-31
MOAB
Duke University
Phase 2 Recruiting
NCT04631029 2025-10-03
Testing the Addition of an Anti-cancer Drug, Entinostat, to the Usual Chemotherapy and Immunotherapy Treatment (Atezolizumab, Carboplatin and Etoposide) for Previously Untreated Aggressive Lung Cancer That Has Spread
National Cancer Institute (NCI)
Phase 1 Completed
NCT03174197 2025-09-24
Atezolizumab in Combination With Temozolomide and Radiation Therapy in Treating Patients With Newly Diagnosed Glioblastoma
M.D. Anderson Cancer Center
Phase 1/2 Completed
NCT04808245 2025-09-22
INTERCEPT-H3
German Cancer Research Center
Phase 1 Active not recruiting
NCT04400474 2025-06-19
CABATEN
Grupo Espanol de Tumores Neuroendocrinos
Phase 2 Completed
NCT03673787 2025-05-14
IceCAP
Institute of Cancer Research, United Kingdom
Phase 1/2 Active not recruiting
NCT04160494 2025-05-11
D2C7-IT With Atezolizumab for Recurrent Gliomas
Duke University
Phase 1 Active not recruiting
NCT03417544 2025-04-02
Atezolizumab + Pertuzumab + Trastuzumab In CNS Mets In BC
Dana-Farber Cancer Institute
Phase 2 Active not recruiting
NCT06328036 2024-12-30
Testing the Combination of Anti-cancer Drugs Tiragolumab and Atezolizumab to Improve Outcomes for Patients With Recurrent Glioblastoma
National Cancer Institute (NCI)
Phase 2 Withdrawn
NCT04610684 2024-03-13
Chemotherapy and Atezolizumab for Patients With Extensive Stage Small Cell Lung Cancer (SCLC) With Untreated, Asymptomatic Brain Metastases
Hoosier Cancer Research Network
Phase 2 Terminated
NCT03158389 2023-09-28
N²M²
University Hospital Heidelberg
Phase 1/2 Completed
NCT03973879 2020-02-11
Combination of PVSRIPO and Atezolizumab for Adults With Recurrent Malignant Glioma
Duke University
Phase 1/2 Withdrawn